Cover Story HBA Woman of the Year
At the helm of a billion-dollar communcations firm, Lynn O'Connor Vos wants to improve the reputation of pharma—and its marketers—for the sake of tomorrow's business leaders.Features Deal Making
Keys to Success
Michael Curran-Hays and Martin Wing
The playing field has leveled when it comes to pharma and biotech companies teaming up to develop or market products, making joint efforts an increasingly popular strategy.
Anthony Farino and Timothy Nugent
John T. Bentivoglio and John Shakow
Every quarter, pharma manufacturers are faced with the high-stakes—and confusing—process of price reporting.
A rise in the number of challenges by generic manufacturers to brand name drug patents is complicating the way pharma manages its products.
Pharma in the News
Stephen J. Porth and George P. Sillup
Maybe the industry isn't paranoid after all. When it comes to ethical issues, pharma generates a lot of negative ink.
Unleashing the Promise
Amid political and ethical contentions over stem cell research, several companies are moving full steam ahead on bringing stem cell-based therapeutics to market.
News & Analysis Leading Indicators
Insurance companies waste no time sponsoring prescription drug plans » PhRMA's on a quest to win patients over » India's new patent law grants 20-year monopolies » FDA faces pressure to develop guidances for testing generic biotech therapies.
Public trust in FDA wanes post-Vioxx » PharmD's more popular than ever » Outsourcing soars.
Dr. Jerry Avorn, Harvard medical professor, thinks science—not marketing—should drive pharma.
A new approach to drug safety is needed at FDA. The agency says it can handle the problem internally—but critics are skeptical.
Novartis' recent acquisition of a German generics manufacturer could mean a shift in power for the top spot in generic drug making.
Status quo definitions of productivity no longer cut it. Leaders today are charged with fostering offices that stimulate creative thought, and inspire innovation.
Sander A. Flaum
Strategy & Tactics Direct to Consumer
Last year, Pfizer got warned about not including risk information in its reminder ads for Viagra. Are these ads worth the risk for pharma companies—and consumers?